- Price
- $478.71
- Day
- +1.70%
- Mkt Cap
- $121.50B
- 52W Range
- $362.50 – $533.67
- Volume
- 1.93M
- Beta
- 0.30
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.
Read full article
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read full article
Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.73 per share, missing the Zacks Consensus Estimate of $4.79 per share. This compares to earnings of $4.52 per share a year ago.
Read full article
Vertex Pharmaceuticals on Monday raised the upper end of its annual revenue forecast, banking on robust demand for its cystic fibrosis treatments.
Read full article
Vertex Pharmaceuticals NASDAQ: VRTX reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX.
Read full article
Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript
Read full article
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance. “Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pilla.
Read full article
Amundi lifted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 12.9% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,472,496 shares of the pharmaceutical company's stock after acquiring an additional 168,335 shares during the period. Amundi owned approximately 0.58% of Vertex Pharmaceuticals worth
Read full article
Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read full article
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.
Read full article
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read full article
Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article